Chennai, Jul 19 (UNI) ABL Biotechnologies Ltd, a publicly held, technology intensive company has signed a Memorandum of Understanding (MOU) with Christian Medical College, (CMC)Vellore for joint research in several areas which would have far reaching implications in cost-effective management of various diseases prevalent in the Indian sub-continent.
The company's Chairman K O Issac, told newspersons here that the MOU signals the beginning of an initiative that will bring together technological competence, research expertise and clinical acumen to accelerate the discovery of novel drug targets and therapeutic approaches.
Tuberculosis, Oncology, Cardio-Vascular medicine and nanotechnology based therapy are a few of the projects which the company and CMC will also explore jointly, he added.
He said the company has also launched Invia Health, its own pharmaceutical division recently to cater to the Indian market with a well diversified portfolio of products.
The portfolio of products mainly addressed vascular health , G Ihealth and neuroprotection, especially in diabetics. Infectious diseases being the largest segment, anti-infectives were added during the course of the year, he said.
Innvia Health is now expanding its operations to Kerala followed by Andhra Pradesh, Karnataka and Orissa in August- September. ''This expansion into rest of the south and Orissa will see ''Invia Health'', taking its products to cater to the Cardio-Diabetic segment, including medicines for the management of heart failure.'' said Mr P S Ganeshan, President, Invia Health said.
UNI
The company's Chairman K O Issac, told newspersons here that the MOU signals the beginning of an initiative that will bring together technological competence, research expertise and clinical acumen to accelerate the discovery of novel drug targets and therapeutic approaches.
Tuberculosis, Oncology, Cardio-Vascular medicine and nanotechnology based therapy are a few of the projects which the company and CMC will also explore jointly, he added.
He said the company has also launched Invia Health, its own pharmaceutical division recently to cater to the Indian market with a well diversified portfolio of products.
The portfolio of products mainly addressed vascular health , G Ihealth and neuroprotection, especially in diabetics. Infectious diseases being the largest segment, anti-infectives were added during the course of the year, he said.
Innvia Health is now expanding its operations to Kerala followed by Andhra Pradesh, Karnataka and Orissa in August- September. ''This expansion into rest of the south and Orissa will see ''Invia Health'', taking its products to cater to the Cardio-Diabetic segment, including medicines for the management of heart failure.'' said Mr P S Ganeshan, President, Invia Health said.
UNI
Oneindia Login